Provided by Tiger Fintech (Singapore) Pte. Ltd.

Ionis Pharmaceuticals

28.40
+0.05000.18%
Post-market: 28.400.00000.00%16:25 EDT
Volume:841.01K
Turnover:23.81M
Market Cap:4.51B
PE:-9.35
High:28.76
Open:28.31
Low:28.04
Close:28.35
Loading ...

Buy Rating for Ionis Pharmaceuticals: Strong Financials and Promising Clinical Developments

TIPRANKS
·
07 Nov 2024

Ionis Pharmaceuticals: Strategic Developments and Robust Pipeline Justify Buy Rating

TIPRANKS
·
07 Nov 2024

Ionis Reports Late-Stage Trial Design in Angelman Syndrome

MT Newswires Live
·
07 Nov 2024

Ionis Pharmaceuticals Beats on Revenue

Motley Fool
·
07 Nov 2024

Compared to Estimates, Ionis Pharmaceuticals (IONS) Q3 Earnings: A Look at Key Metrics

Zacks
·
06 Nov 2024

Stock Track | Ionis Pharmaceuticals Soars on Positive Angelman Syndrome Drug Update, Q3 Results

Stock Track
·
06 Nov 2024

Ionis Pharmaceuticals (IONS) Reports Q3 Loss, Tops Revenue Estimates

Zacks
·
06 Nov 2024

Ionis Pharmaceuticals' Q3 Loss Narrows, Revenue Decreases

MT Newswires Live
·
06 Nov 2024

Ionis Pharmaceuticals Q3 2024 Adj EPS $(0.72) Beats $(1.16) Estimate, Sales $134.00M Beat $130.13M Estimate

Benzinga
·
06 Nov 2024

BRIEF-Ionis Reports Third Quarter 2024 Financial Results

Reuters
·
06 Nov 2024

Ionis Pharmaceuticals: Q3 Earnings Snapshot

Associated Press Finance
·
06 Nov 2024

BRIEF-Ionis Announces Pivotal Phase 3 Trial Design For ION582 In Angelman Syndrome

Reuters
·
06 Nov 2024

Ionis Pharmaceuticals Inc - Bayley-4 Expressive Communication Selected as Phase 3 Primary Endpoint

THOMSON REUTERS
·
06 Nov 2024

Ionis Announces Pivotal Phase 3 Trial Design for Ion582 in Angelman Syndrome

THOMSON REUTERS
·
06 Nov 2024

Ionis Pharmaceuticals Inc - Positive End of Phase 2 Discussion With FDA

THOMSON REUTERS
·
06 Nov 2024

Ionis Pharmaceuticals Inc - Ion582 Phase 3 Study Initiation Planned for H1 2025

THOMSON REUTERS
·
06 Nov 2024

BRIEF-Ionis Pharmaceuticals Q3 Revenue USD 134 Million Vs. IBES Estimate USD 130.1 Million

Reuters
·
06 Nov 2024

Ionis Pharmaceuticals Inc FY2024 Shr View $-3.74, REV View $623.9 Mln -- Lseg Ibes Data

THOMSON REUTERS
·
06 Nov 2024

Ionis Pharmaceuticals Inc: Qtrly Loss per Shr $0.95

THOMSON REUTERS
·
06 Nov 2024

Ionis Pharmaceuticals Q3 Net Income USD -140 Million

THOMSON REUTERS
·
06 Nov 2024